ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick Farrell will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Monday, September 30, 2019 at 9:30 a.m. ET.
Founded in 1989, ResMed began as ResCare, a management buy-out of sleep apnea technology from Baxter Healthcare. Today, ResMed is the world’s leading software-driven medical device company with over 4.5 billion nights of medical sleep and respiratory care data and over 10 million 100% cloud connectable medical devices in the market.
“From a single A$1.25 million investment, ResMed has transformed into a A$28 billion (US$19 billion) connected health leader, changing over 100 million lives a year with either a cloud-connected medical device or through software support of an out-of-hospital care agency,” said Farrell. “I’m proud to be one of 7,500-plus ResMedians worldwide dedicated to improving the quality of so many lives, and one of countless investors who have long seen and supported the value of all that ResMed creates. And we are just getting started.”
The event will be broadcast live from the NYSE and will be live streamed online at https://www.nyse.com/bell.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005117/en/
Contacts
For investors
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
For media
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
Source: ResMed